SLC16A3 and cancer: We speculate a novel limotherapy for treating cancers that disturbs the relationship of metabolic symbiosis by controlling the MCT4 expression and/or specifically blocking the MCT1 expression, the possible mechanisms including lactate shuttles, immune suppression, oxidative stress, and neovascularization.